EagleBio/α-突触核蛋白预制原纤维(2型)/SPR-317

价格
面议
货号:SPR-317
浏览量:127
品牌:EagleBio
服务
全国联保
正品保证
正规发票
签订合同
商品描述

Alpha Synuclein Preformed Fibrils (Type 2)

The Alpha Synuclein Preformed Fibrils (Type 2) is For Research Use Only

Specificity: ~14.46 kDa
Species: Human
Expression System: E. coli
Buffer: PBS pH 7.4
Storage Temperature: -80ºC
Alternate Name: Active Human Recombinant Alpha Synuclein Preformed Fibrils (Type 2), Alpha synuclein PFFs, Alpha synuclein aggregates, Alpha synuclein protein aggregates, Alpha
Synuclein aggregates, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, SYN protein, Parkinson disease familial 1 Protein

Product manufactured in Canada by StressMarq.


Scientific Background

Alpha-Synuclein (SNCA) is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals . Alpha-synuclein is highly expressed in the mitochondria of the olfactory bulb, hippocampus, striatum and thalamus. Functionally, it has been shown to significantly interact with tubulin, and may serve as a potential microtubule-associated protein. It has also been found to be essential for normal development of the cognitive functions; inactivation may lead to impaired spatial learning and working memory. SNCA fibrillar aggregates represent the major non A-beta component of Alzheimers disease amyloid plaque, and a major component of Lewy body inclusions, and Parkinson’s disease. Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.


Related Products

Active Human Recombinant SNCA Protein Monomer (Type 2)
Active Human Recombinant SNCA Protein Monomer (Type 1)
Active Human Recombinant SNCA Preformed Fibrils (Type 1)

EagleBio的iLite®分析就绪细胞iLite®  技术基于报告基因检测格式,经过修改和适用于整个药物开发周期中的应用以及生物药物的监测。这些细胞系可以开发用于任何生物制药靶标,并且可以使用相同的细胞系轻松设置药物效力(即药物活性)的测定方法。检验就绪的细胞经过基因工程处理,可与报告基因检验技术一起使用,以检测药物效力和NAb。